摘要
间质-上皮细胞转化因子(mesenchymal-epithelial transition factor,MET)基因是非小细胞肺癌(nonsmall cell lung cancer,NSCLC)的一种重要肿瘤驱动基因,针对MET 14外显子的跳跃突变的靶向治疗药物给患者带来新的希望。目前已经上市或者即将上市的MET抑制剂包括:克唑替尼、卡博替尼、沃利替尼和Tepotinib等。MET抑制剂的客观缓解率较高,并且安全性良好。但是,MET抑制剂的耐药不可避免,因此需要重视对于耐药机制的研究。肝细胞生长因子(hepatocyte growth factor,HGF)/MET信号通路抑制剂与其他药物的联合应用,对于抑制和逆转耐药可能发挥重要作用。
Mesenchymal-epithelial transition factor(MET)gene is an important tumor driver gene of non-small cell lung cancer(NSCLC).Drugs targeting MET 14 exon skipping mutation bring new hope to patients.MET inhibitors that are currently on the market or are about to be marketed include:crizotinib,cabozantinib,savolitinib and tepotinib.The objective response rate of MET inhibitors is high,and the safety is good.However,resistance of MET-tyrosine kinase inhibitor(TKI)is inevitable,so it is necessary to pay attention to the study of drug resistance mechanism.In addition,the combined use of hepatocyte growth factor(HGF)/MET inhibitors and other drugs may play an important role in inhibiting and reversing drug resistance.
作者
韩森
马旭
方健
Sen HAN;Xu MA;Jian FANG(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2020年第7期609-614,共6页
Chinese Journal of Lung Cancer
基金
北京大学肿瘤医院科学研究基金项目(No.2020自主-27)资助~~。
